Atinary Technologies, in partnership with Takeda Pharmaceuticals, the largest pharmaceutical company in Japan, has launched a state-of-the-art AI-driven facility in Kendall Square, Cambridge, Massachusetts. Known as the Self-driving Laboratory™, this lab is set to advance the field of drug discovery and chemical research through fully automated, AI-powered workflows. The lab combines Atinary’s no-code AI platform, SDLabs™, with cutting-edge autonomous robotics to create an optimized and highly efficient laboratory environment.
Key Innovations of the Atinary Lab
The Atinary Lab will serve as a demonstration hub where can be observed firsthand the transformative potential of integrating AI, robotics, and automation in research and development (R&D). The lab will produce high-quality, reproducible, and ML-ready (machine learning-ready) datasets, essential for refining AI algorithms and enhancing the performance of large language models, transfer learning, and multi-fidelity learning techniques. This level of data quality is expected to continuously improve Atinary’s algorithms, allowing for more effective handling of complex R&D challenges.
Results and Future Potential
The collaboration between Atinary and Takeda, initiated in 2023, has already yielded promising results. Through Atinary’s machine learning algorithms, early projects demonstrated remarkable gains in yield efficiency—from less than 50% to over 90%—within only three iterative cycles. The success of these early-stage projects has spurred the expanded partnership, and Atinary Lab’s future efforts will aim to replicate and build on these results at scale.
